Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
4.10% $9.65
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 567.29 mill |
EPS: | -4.71 |
P/E: | -2.05 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 58.79 mill |
Avg Daily Volume: | 0.294 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.05 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.35x |
Company: PE -2.05 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.753 (-92.19%) $-8.90 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 8.29 - 11.01 ( +/- 14.10%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-26 | Schwarzer Fred | Buy | 38 583 | Common Stock |
2024-03-26 | Keyt Bruce | Buy | 24 019 | Common Stock |
2024-03-28 | Baker Bros. Advisors Lp | Buy | 89 407 | Common Stock |
2024-03-27 | Baker Bros. Advisors Lp | Buy | 8 439 | Common Stock |
2024-03-27 | Baker Bros. Advisors Lp | Buy | 17 101 | Common Stock |
INSIDER POWER |
---|
83.60 |
Last 99 transactions |
Buy: 2 483 925 | Sell: 237 828 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $9.65 (4.10% ) |
Volume | 0.234 mill |
Avg. Vol. | 0.294 mill |
% of Avg. Vol | 79.58 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | buy | $13.06 | N/A | Active |
---|
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.